Today’s Stock On Watch: Fresenius Medical Care AG & Co. (ADR) Sets 1 Year Low; Strong Momentum for Sellers

Today's Stock On Watch: Fresenius Medical Care AG & Co. (ADR) Sets 1 Year Low; Strong Momentum for Sellers

The stock of Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) hit a new 52-week low and has $36.73 target or 6.00% below today’s $39.07 share price. The 9 months bearish chart indicates high risk for the $23.90 billion company. The 1-year low was reported on Nov, 14 by If the $36.73 price target is reached, the company will be worth $1.43B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 146,633 shares traded hands. Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) has declined 10.81% since April 12, 2016 and is downtrending. It has underperformed by 15.79% the S&P500.

Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) Ratings Coverage

Out of 6 analysts covering Fresenius Medical (NYSE:FMS), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Fresenius Medical has been the topic of 8 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Goldman Sachs maintained the stock with “Buy” rating in Tuesday, September 22 report. The stock has “Overweight” rating given by JP Morgan on Monday, January 4. RBC Capital Markets maintained Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) rating on Friday, July 31. RBC Capital Markets has “Sector Perform” rating and $40 price target. RBC Capital Markets maintained it with “Sector Perform” rating and $42 target price in Wednesday, November 4 report. The rating was downgraded by Societe Generale to “Buy” on Thursday, August 13. The rating was initiated by Nomura on Thursday, March 17 with “Buy”. The company was upgraded on Thursday, September 3 by Goldman Sachs. The rating was upgraded by Jefferies on Friday, July 8 to “Hold”.

According to Zacks Investment Research, “Fresenius Medical Care provides a range of products for both treatment modalities, hemmodialysis and peritoneal dialysis, and is a full service provider of dialysis care. They provide dialysis treatment and related laboratory and diagnostic services at more than 1,000 dialysis clinics. They manufacture a range of hemodialysis machines, dialyzers, peritoneal dialysis solutions and ancillary products. They have operations in approximately 100 countries.”

More notable recent Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) news were published by: which released: “Fresenius Medical Care AG & Co. KGaA ADR” on December 09, 2009, also with their article: “Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?” published on April 02, 2014, published: “Fresenius Medical Care lifts 2016 profit guidance” on October 29, 2015. More interesting news about Fresenius Medical Care AG & Co. (ADR) (NYSE:FMS) were released by: and their article: “17 Health Care Providers & Services Stocks to Sell Now” published on November 08, 2016 as well as‘s news article titled: “10 Health Care Providers & Services Stocks to Sell Now” with publication date: November 01, 2016.

FMS Company Profile

Fresenius Medical Care AG & Co. KGaA (FMC AG & CO. KGAA), incorporated on February 10, 2006, is a kidney dialysis company. The Firm provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Firm operates through four divisions: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America. The Firm develops and makes a range of dialysis machines, systems and disposable products. The Company’s dialysis business provides dialysis treatment at its own dialysis clinics and supplies the clinics with a range of products. In addition, it sells dialysis products to other dialysis service providers. The Company’s Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, and health plan services and urgent care services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment